Death, limb amputations, and new TECs in patients with acute HIT and isolated thrombocytopenia treated with lepirudin and in the control group
. | Lepirudin group with isolated thrombocytopenia, n = 91 . | . | . | . | . | Lepirudin group with recent TECs, n = 30† . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Events during treatment . | Events following treatment . | All patients with events . | Control group, n = 47* . | P. log-rank test . | Events during treatment . | Events following treatment . | All patients with events . | ||||
| Median observation period, | ||||||||||||
| d (range) | 11.0 (1-68) | 9.0 (0-32) | 24.0 (3-73) | 15.0 (1-141) | NA | 9.5 (1-24) | 13.7 (1-36) | 26.2 (9-48) | ||||
| New thrombosis, no. (%) | 1 (1.1) | 3 (3.3) | 4 (4.4) | 7 (14.9) | .02 | 4 (13.3) | 1 (3.3) | 5 (16.6) | ||||
| Limb amputation, no. (%) | 2 (2.2) | 1 (1.1) | 3 (3.3)‡ | 0 (0.0) | .2424 | 4 (13.3) | 1 (3.3) | 5 (16.6) | ||||
| Death, no. (%) | 5 (5.5) | 8 (8.8) | 13 (14.3) | 10 (21.3) | .0937 | 0 (0.0) | 3 (10.0) | 3 (10.0) | ||||
| Combined end point, no. (%) | 8 (8.8) | 10 (11.0) | 18 (19.8) | 14 (29.8) | .0281 | 5 (16.6) | 5 (16.6) | 10 (33.3) | ||||
. | Lepirudin group with isolated thrombocytopenia, n = 91 . | . | . | . | . | Lepirudin group with recent TECs, n = 30† . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Events during treatment . | Events following treatment . | All patients with events . | Control group, n = 47* . | P. log-rank test . | Events during treatment . | Events following treatment . | All patients with events . | ||||
| Median observation period, | ||||||||||||
| d (range) | 11.0 (1-68) | 9.0 (0-32) | 24.0 (3-73) | 15.0 (1-141) | NA | 9.5 (1-24) | 13.7 (1-36) | 26.2 (9-48) | ||||
| New thrombosis, no. (%) | 1 (1.1) | 3 (3.3) | 4 (4.4) | 7 (14.9) | .02 | 4 (13.3) | 1 (3.3) | 5 (16.6) | ||||
| Limb amputation, no. (%) | 2 (2.2) | 1 (1.1) | 3 (3.3)‡ | 0 (0.0) | .2424 | 4 (13.3) | 1 (3.3) | 5 (16.6) | ||||
| Death, no. (%) | 5 (5.5) | 8 (8.8) | 13 (14.3) | 10 (21.3) | .0937 | 0 (0.0) | 3 (10.0) | 3 (10.0) | ||||
| Combined end point, no. (%) | 8 (8.8) | 10 (11.0) | 18 (19.8) | 14 (29.8) | .0281 | 5 (16.6) | 5 (16.6) | 10 (33.3) | ||||
NA indicates not applicable.
Contemporaneous control patients were treated with phenprocoumon, 11 (23.4%), acetylsalicylic acid, 5 (10.6%), and no treatment, 31 (66.0%). Patients may have suffered more than one event.
Patients with acute isolated HIT but recent non-HIT-related TECs. These patients were excluded from the present study.
One limb amputation occurred prior to the start of lepirudin treatment. This event was not included in this table or in the comparison with the control group.